FMC Corporation's Q2 2025: Unpacking Contradictions in India Strategy, Rynaxypyr Pricing, and Market Pressures

India Business Strategy, Pricing Strategy for Rynaxypyr, Rynaxypyr Pricing Strategy and Outlook, Pricing Trajectory and Competitive Pressure are the key contradictions discussed in FMC Corporation's latest 2025Q2 earnings call.



Operational and Strategic Adjustments:
- FMC Corporation's second quarter sales were 1% higher than the prior year, with volume growth of 6%.
- The company implemented actions to normalize channel inventory levels and focused on growth strategies for key regions and product lines.

Cost Management and EBITDA Growth:
- Adjusted EBITDA for the second quarter was $207 million, 2% higher than the prior year.
- Growth was driven by lower costs from lower raw materials, better fixed cost absorption, and restructuring actions.

Regional Performance and Market Challenges:
- Revenue in EMEA and Latin America showed improvements, while North America experienced a 5% decline due to expected destocking in Canada.
- Asia's performance was impacted by ongoing destocking in India, which led to a decline in sales.

India Business Strategy and Financial Impact:
- FMC announced the divestment of its commercial business in India, which is expected to resolve challenges and improve financial performance.
- The decision comes amidst intense generic competition and high working capital requirements in the Indian market.